MedTrace Logo

Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis

NCT04278040 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-02-20

No results posted yet for this study

Summary

This non-randomised open-label prospective pilot study evaluates the safety and efficacy of inhalations of ultra-low doses of alkylating drug melphalan for the treatment of non-cystic fibrosis bronchiectasis. All patients will receive 0,1 mg of melphalan in 5 daily inhalations 1 time per day.

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Interventions

DRUG

Melphalan

Inhalations with low doses of Melphalan for 5 consequent days

Sponsors & Collaborators

  • Moscow State University of Medicine and Dentistry

    collaborator OTHER

  • Federal State Budgetary Institution, Pulmonology Scientific Research Institute

    lead OTHER_GOV

Principal Investigators

  • Kirill Zykov, Prof · Federal State Budgetary Institution, Pulmonology Scientific Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-20
Primary Completion
2021-12-01
Completion
2021-12-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278040 on ClinicalTrials.gov